Review
Platelet dysfunction in central obesity

https://doi.org/10.1016/j.numecd.2009.01.006Get rights and content

Abstract

Central obesity is a relevant risk factor for major cardiovascular events due to the atherosclerotic involvement of coronary, cerebral and lower limb arterial vessels.

A major role in the increased cardiovascular risk is played by platelets, which show an increased activation and a reduced sensitivity to the physiological and pharmacological antiaggregating agents. This review focuses on platelet dysfunction in central obesity.

The mechanisms involved are related to: i) the reduced sensitivity to insulin and other substances acting via intracellular cyclic nucleotides, such as nitrates and prostacyclin; ii) the altered intracellular ionic milieu with elevated cytosolic Ca2+; and iii) the increased oxidative stress, which elicits isoprostane production from arachidonic acid.

Therapeutic guidelines recommend a multifactorial prevention of cardiovascular disease including antiplatelet drugs in high risk patients, even though, at present, the protective effect of antiplatelet therapy in obese, insulin resistant subjects has not been evaluated by specific trials. Some reports, however, suggest a decreased sensitivity to the antiaggregating effects of both acetylsalicylic acid (aspirin) and thienopyridines in human obesity. Platelet defects may play a pivotal role in the reduced efficacy of antiplatelet therapy in obese subjects in the setting of cardiovascular prevention and acute coronary syndrome treatment. Thus, a specifically tailored antiaggregating therapy is likely necessary in obese, insulin resistant subjects, especially in the presence of type 2 diabetes mellitus.

Section snippets

Introduction review criteria

Central obesity is independently associated with an elevated risk of cardiovascular morbidity and mortality due to atherothrombotic events [1], [2].

The susceptibility to the clinical manifestations of atherosclerosis is related to the presence of low grade inflammation together with the variable co-existence of impaired glucose metabolism, atherogenic dyslipidemia, arterial hypertension, endothelial dysfunction and a prothrombotic state [2], [3].

The metabolic syndrome – which is defined on the

Platelets in haemostasis and atherothrombosis

Platelets are a pivotal component of the physiologic haemostatic balance and of a first line defence against the loss of endothelium integrity; furthermore, they are involved in inflammation, atherogenesis and atherothrombosis through the ability to adhere to injured vessels, to accumulate at sites of vascular injury and to release bioactive mediators [7].

Endothelium damage or loss facilitates the interaction among constituents of the subendothelial matrix and circulating platelets, which

Alterations of platelet function in obesity

The presence of a prothrombotic state accounts in part for the high prevalence of cardiovascular events in patients with visceral obesity, despite the control of traditional risk factors [33]. Recent studies focused the attention on the pathogenetic role of platelet hyperactivation [34], [35] and reduced sensitivity to the antiaggregating therapy in these conditions.

A variety of defects in platelet function has been identified in human obesity, as summarized in Fig. 1. As clearly evidenced,

Antiplatelet therapy in patients affected by obesity

For the reasons mentioned above, the platelet alterations described in central obesity and in the other insulin resistant states provide a rationale for antiplatelet therapy even in primary prevention [31], [128].

Conclusions

Subjects affected by central obesity and insulin resistance frequently develop premature and extensive atherosclerotic lesions [144] and are at high risk of coronary, cerebrovascular and peripheral artery disease [144]. Prevention and treatment of cardiovascular events are, therefore, a major challenge in these patients.

Abnormalities of platelet function – together with activated coagulation, hypofibrinolysis and endothelial dysfunction – result in an elevated thrombotic tendency and play a

Acknowledgement

This study was supported by a grant from Italian Ministero dell'Istruzione, Università e Ricerca (MIUR), COFIN 2004 within the project “The Molecular basis of insulin resistance and their importance in the pathogenesis of the alterations of the vessel wall”; Local Coordinator: Prof. Giovanni Anfossi; National Coordinator: Prof. Amalia Bosia.

References (148)

  • Y. Tavil et al.

    Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease

    Thromb Res

    (2007)
  • G. De Pergola et al.

    sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors

    Nutr Metab Cardiovasc Dis

    (2008)
  • K. Gokulakrishnan et al.

    Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome – the Chennai Urban Rural Epidemiology Study

    Metabolism

    (2006)
  • F.D. George

    Microparticles in vascular diseases

    Thromb Res

    (2008)
  • S. Nomura et al.

    Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus

    Atherosclerosis

    (1995)
  • T. Murakami et al.

    Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity

    Thromb Res

    (2007)
  • C. Falcon et al.

    The platelet insulin receptor: detection, partial characterization, and search for a function

    Biochem Biophys Res Commun

    (1988)
  • P. López-Aparicio et al.

    Insulin induced phosphorylation and activation of the cGMP-inhibited cAMP phosphodiesterase in human platelets

    Biochem Biophys Res Commun

    (1992)
  • I. Russo et al.

    Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation

    Thromb Res

    (2002)
  • I. Russo et al.

    Comparison between the effects of the rapid recombinant insulin analog Lispro (Lys B28, Pro B29) and those of human regular insulin on platelet cyclic nucleotides and aggregation

    Thromb Res

    (2003)
  • E. Butt et al.

    cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets

    J Biol Chem

    (1994)
  • J. Yamanishi et al.

    Effect of cyclic AMP on cytoplasmic free calcium in human platelets stimulated by thrombin: direct measurement with quin2

    Thromb Res

    (1983)
  • Y. Kawahara et al.

    Inhibitory action of guanosine 3′5′-monophosphate on thrombin-induced calcium mobilization in human platelets

    Thromb Res

    (1984)
  • I.A. Ferreira et al.

    IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi

    J Biol Chem

    (2004)
  • Y.Y. Chirkov et al.

    Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets

    J Am Coll Cardiol

    (2001)
  • A. Qasim et al.

    Adipokines, insulin resistance, and coronary artery calcification

    J Am Coll Cardiol

    (2008)
  • P.M. Piatti et al.

    Insulin resistance, hyperleptinemia and endothelial dysfunction in coronary restenosis

    Curr Opin Pharmacol

    (2005)
  • P. Kougias et al.

    Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease

    J Surg Res

    (2005)
  • National Task Force on the Prevention and Treatment of Obesity

    Overweight, obesity, and health risk

    Arch Intern Med

    (2000)
  • J.P. Després

    Cardiovascular disease under the influence of excess visceral fat

    Crit Pathw Cardiol

    (2007)
  • I. Mertens et al.

    Obesity, haemostasis and the fibrinolytic system

    Obes Rev

    (2002)
  • A.D. Michelson

    How platelets work: platelet function and dysfunction

    J Thromb Thrombolysis

    (2003)
  • J. Lefkovits et al.

    Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

    N Engl J Med

    (1995)
  • M. Gawaz

    Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium

    Cardiovasc Res

    (2004)
  • S. Massberg et al.

    A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo

    J Exp Med

    (2003)
  • Z.M. Ruggeri

    Platelets in atherothrombosis

    Nat Med

    (2002)
  • G. Davì et al.

    Platelet activation and atherothrombosis

    N Engl J Med

    (2007)
  • R. Jokl et al.

    Platelet plasminogen activator inhibitor 1 in patients with type II diabetes

    Diabetes Care

    (1994)
  • R. Jokl et al.

    Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes

    Diabetes Care

    (1995)
  • T. Cyrus et al.

    Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice

    Circulation

    (2002)
  • D. Praticò et al.

    Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice

    Proc Natl Acad Sci U S A

    (2001)
  • A.J. Cayatte et al.

    The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis

    Arterioscler Thromb Vasc Biol

    (2000)
  • V. Henn et al.

    CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

    Nature

    (1998)
  • E. Lindmark et al.

    Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression

    Arterioscler Thromb Vasc Biol

    (2000)
  • F. Mach et al.

    Reduction of atherosclerosis in mice by inhibition of CD40 signalling

    Nature

    (1998)
  • S. Moncada et al.

    Nitric oxide and the vascular endothelium

    Handb Exp Pharmacol

    (2006)
  • M.W. Radomski et al.

    The biological and pharmacological role of nitric oxide in platelet function

    Adv Exp Med Biol

    (1993)
  • D.H. Maurice et al.

    Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP

    Mol Pharmacol

    (1990)
  • J.E. Freedman et al.

    Nitric oxide released from activated platelets inhibits platelet recruitment

    J Clin Invest

    (1997)
  • G. Anfossi et al.

    Platelet resistance to the anti-aggregating agents in the insulin resistant states

    Curr Diabetes Rev

    (2006)

    • Cited by (123)

    • Obesity: Effects on bone marrow homeostasis and platelet activation

      2023, Thrombosis Research

    • The rate of platelet activation determines thrombus size and structure at arterial shear

      2023, Journal of Thrombosis and Haemostasis

    • Insulin resistance in Alzheimer's disease: The genetics and metabolomics links

      2023, Clinica Chimica Acta

    • The crosstalk between platelets and body fat: A reverse translational study

      2021, Clinical Nutrition
      Citation Excerpt :

      These associations persisted even after adjusting for many confounding factors including hsCRP (high sensitivity C reaction protein) level which can reflect the systemic inflammation [6]. Individuals with obesity are commonly accompanied by platelet dysfunction [7,8]. Platelets are circulating, anucleate, and disc-shaped cells that are readily available for cellular interactions during their rapid systemic flow with the bloodstream.

    • Platelet-derived chemokines in inflammation and atherosclerosis

      2019, Cytokine

    • The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk

      2023, International Journal of Molecular Sciences
    View all citing articles on Scopus
    View full text
    Copyright © 2009 Elsevier B.V. All rights reserved.